Translate
About
Instil Bio Inc. (NASDAQ:TIL) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 27 2026
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jan 6 2026
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Nov 13 2025
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Sep 10 2025
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
Aug 13 2025
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Recent Videos
Top Movers 🌟 | 2026-01-06 | #CELG-RI #AZI #MOBX #SKYQ #TIL #ALMS #stock #stocks
Jan 06, 2026
Instil Bio's 8-K: My Key Takeaway on Their Financials
Nov 15, 2025
Instil Bio Inc.: My Concern Amidst '2510 Hopes
Nov 15, 2025
TIL Instil Bio, Inc. Stock: 3 Catalysts After WCLC Sept 9 - Thursday Predicted Opening Price? 🚀
Sep 10, 2025
Financials
Revenue
$0
Market Cap
$54.46 M
EPS
-10.70